Jul 27, 2024, 22:01
Day One Biopharmaceuticals announces a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib
Day One Biopharmaceuticals shared a post on LinkedIn:
”We are pleased to announce a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib. This collaboration highlights our shared commitment to bring novel therapeutics to patients worldwide who have limited treatment options. Learn more.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 19, 2024, 08:27
Dec 19, 2024, 08:12
Dec 19, 2024, 08:08
Dec 19, 2024, 07:51
Dec 19, 2024, 07:45
Dec 19, 2024, 07:38
Dec 19, 2024, 07:27
Dec 19, 2024, 07:24